Maspin expression in adenocarcinoma of the ampulla of Vater: Relation with clinicopathological parameters and apoptosis

Anticancer Research

Volumn 27, Issue 2, 2007, Pages 1059-1065

  Blandamura, Stella ^a   D'Alessandro, Emiliano ^a   Guzzardo, Vincenza ^a   Giacomelli, Luciano ^a   Moschino, Paolo ^b   Parenti, Anna ^a   Ninfo, Vito ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Ampulla of Vater; Apoptosis; Maspin; Pancreatic adenocarcinoma

Indexed keywords

KI 67 ANTIGEN; MASPIN; PEPTIDES AND PROTEINS; PROTEIN M30; PROTEIN P53; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADULT; AGED; APOPTOSIS; ARTICLE; CELL NUCLEUS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; FISHER EXACT TEST; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KRUSKAL WALLIS TEST; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RANK SUM TEST; VATER PAPILLA CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; AMPULLA OF VATER; APOPTOSIS; COHORT STUDIES; COMMON BILE DUCT NEOPLASMS; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; SERPINS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34247130176     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Maass N, Hojo T, Zhang M, Sager R, Jonat W and Nagasaki K: Maspin - a novel protease inhibitor with tumor-suppressing activity in breast cancer. Acta Oncol 39: 931-934, 2000.
2. Schneider SS, Schick C, Fish KE, Miller E, Pena JC, Treter SD, Hui SM and Silverman GA: A serine proteinase inhibitor locus at 18q21.3 contains a tandem duplication of the human squamous cell carcinoma ahtigen gene. Proc Natl Acad Sci USA 92: 3147-3151, 1995.
3. Blacque OE and Worrall DM: Evidence for a direct interaction between the tumor suppressor Serpin, Maspin, and types I and II collagen. J Biol Chem 27: 10783-10788, 2002.
4. Ngamkitidechakul C, Warejcka DJ, Burke JM, O'Brien WJ and Twining SS: Sufficiency of the reactive site loop of maspin for induction of cell-matrix adhesion and inhibition of cell invasion. J Biol Chem 278: 31796-31806, 2003.
5. Woenckhaus M, Bubendorf L, Dalquen P, Foerster J, Blaszyk H, Mirlacher M, Soler M, Dietmaier W, Sauter G, Hartmann A and Wild PJ: Nuclear and cytoplasmic Maspin expression in primary non-small cell lung cancer. J Clin Pathol DOI: 10.1136/jcp.2005.
6. Surowiak P, Materna V, Drag-Zalesinska M, Wojnar A, Kaplenko I, Spaczynski M, Dietel M, Zabel M and Lage H: Maspin expression is characteristic for cisplatin-sensitive ovarian cancer cells and for ovarian cancer cases of longer survival rates. Int J Gynecol Pathol 25: 131-139, 2006.
7. Gynecologic Oncology Group: Secord AA, Lee PS, Darcy KM, Havrilesky LJ, Grace LA, Marks JR and Berchuck A: Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study. Gynecol Oncol 101: 390-397, 2006.
8. Solomon LA, Munkarah AR, Schimp VL, Arabi MH, Morris RT, Nassar H and Ali-Fehmi R: Maspin expression and localization impact on angiogenesis and prognosis in ovarian cancer. Gynecol Oncol 101: 385-389, 2006.
9. Dietmaier W, Bettstetter M, Wild PJ, Woenckhaus M, Rummele P, Hartmann A, Dechant S, Blaszyk H, Pauer A, Klinkhammer-Schalke M and Hofstadter F: Nuclear maspin expression is associated with response to adjuvant 5-fluorouracil based chemotherapy in patients with stage III colon cancer. Int J Cancer 118: 2247-2254, 2006.
10. Lonardo F, Li X, Siddiq F, Singh R, Al-Abbadi M, Pass HI and Sheng S: Maspin nuclear localization is linked to favorable morphological features in pulmonary adenocarcinoma. Lung Cancer 51: 31-39, 2006.
11. Tahmatzopoulos A, Sheng S and Kyprianou N: Maspin sensitizes prostate cancer cells to doxazosin-induced apoptosis. Oncogene 24: 5375-5383, 2005.
12. Bass R, Moreno Fernandez A-M and Ellis V: Maspin inhibits cell migration in the absence of protease inhibitory activity. J Biol Chem 277: 46845-46848, 2002.
13. Son HJ, Sohn T-S, Song SY, Lee JH and Rhee JC: Maspin expression in human gastric adenocarcinoma. Pathol Int 52: 508-513, 2002.
14. Zhang W, Shi HY and Zhang M: Maspin overexpression modulates tumor cell apoptosis through the regulation of Bcl-2 family proteins. BMC Cancer DOI: 10.1186/1471-2407-5-50.
15. Latha K, Zhang W, Cella N, Shi HY and Zhang M: Maspin mediates increased tumor cell apoptosis upon induction of the mitochondrial permeability transition. Mol Cell Biol 25: 1737-1748, 2005.
16. Leers MP, Kolgen W, Bjorklund V, Bergman T, Tribbick G, Persson B, Bjorklund P, Ramaekers FC, Bjorklund B, Nap M, Jornvall H and Schutte B: Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 187: 567-572, 1999.
17. Stanton KJ, Sidner RA, Miller GA, Cummings OW, Schmidt CM, Howard TJ and Wiebke EA: Analysis of Ki-67 antigen expression, DNA proliferative fraction, and survival in resected cancer of the pancreas. Am J Surg 186: 486-492, 2003.
18. Jeong S, Lee DH, Lee JI, Lee JW, Kwon KS, Kim PS, Kim HG, Shin YW, Kim YS and Kim YB: Expression of Ki-67, p53, and K-ras in chronic pancreatitis and pancreatic ductal adenocarcinoma. World J Gastroenterol 11: 6765-6769, 2005.
19. Vaidya P, Kawarada Y, Higashiguchi T, Yoshida T, Sakakura T and Yatani R: Overexpression of different members of the type 1 growth factor receptor family and their association with cell proliferation in periampullary carcinoma. J Pathol 178: 140-145, 1996.
20. Zhou H, Schaefer N, Wolff M and Fischer HP: Carcinoma of the ampulla of Vater: comparative histologic/immunohistochemical classification and follow-up. Am J Surg Pathol 28: 875-882, 2004.
21. Dorandeu A, Raoul JL, Siriser F, Leclercq-Rioux N, Gosselin M, Martin ED, Ramee MP and Launois B: Carcinoma of the ampulla of Vater: prognostic factors after curative surgery: a series of 45 cases. Gut 40: 350-355, 1997.
22. Maass N, Hojo T, Ueding M, Lüttges J, Klöppel G, Jonat W and Nagasaki K: Expression of the tumor suppressor gene maspin in human pancreatic cancers. Clin Cancer Res 7: 812-817, 2001.
23. Fitzgerald M, Oshiro M, Holtan N, Krager K, Cullen JJ, Futscher BW and Domann FE: Human pancreatic carcinoma cells activate maspin expression through loss of epigenetic control. Neoplasia 5: 427-436, 2003.
24. Ohike N, Maass N, Mundhenke C, Biallek M, Zhang M, Jonat W, Luttges J, Morohoshi T, Kloppel G and Nagasaki K: Clinicopathological significance and molecular regulation of maspin expression in ductal adenocarcinoma of the pancreas. Cancer Lett 199: 193-200, 2003.
25. Di Giorgio A, Alfieri S, Rotondi F, Prete F, Di Miceli D, Ridolfini MP, Rosa F, Covino M and Doglietto GB: Pancreatoduodenectomy for tumors of Vater's ampulla: report on 94 consecutive patients. World J Surg 29: 513-518, 2005.
26. Duffy JP, Hines OJ, Liu JH, Ko CY, Cortina G, Isacoff WH, Nguyen H, Leonardi M, Tompkins RK and Reber HA: Improved survival for adenocarcinoma of the ampulla of Vater: fifty-five consecutive resections. Arch Surg 138: 941-950, 2003.
27. Howe JR, Klimstra DS, Moccia RD, Conlon KC and Brennan MF: Factors predictive of survival in ampullary carcinoma. Ann Surg 228: 87-94, 1998.
28. International Union Against Cancer. TNM Classification of Malignant Tumours. 6th ed. Wiley-Liss, New York, USA 2002.
29. Chieco P, Jonker A and Van Noorden CJF Instrumentation. In: Image cytometry. Chieco P, Jonker A, Van Noorden CJF (eds.). BIOS Scientific Publishers, Oxford, UK, pp. 2032, 2001.
30. Prenzel KL, Warnecke-Eberz U, Brabender J, Baldus SE, Bollschweiler E, Gutschow CA, Drebber U, Hoelscher AH and Schneider PM: Differential c-erbB-1 and c-erbB-2 mRNA expression in cancer of the pancreas compared with cancer of the papilla of Vater. World J Gastroenterol 12: 437-442, 2006.
31. Zhang M, Shi Y, Magit D, Furth PA and Sager R: Reduced mammary tumor progression in WAP-Tag/WAP-maspin bitransgenic mice. Oncogene 19: 6053-6058, 2000.
32. Bailey CM, Khalkhali-Ellis Z, Seftor EA and Hendrix MJC: Biological functions of maspin. J Cell Physiol 209: 617-624, 2006.
33. Shi HY, Liang R, Templeton NS and Zhang M: Inhibition of breast tumor progression by systemic delivery of the maspin gene in a syngeneic tumor model. Mol Ther 5: 755-761, 2005.
34. Sheng S: The promise and challenge toward the clinical application of maspin in cancer. Front Biosci 9: 2733-2745, 2004.
35. Liu J, Yin S, Reddy N, Spencer C and Sheng S: Bax mediates the apoptosis-sensitizing effect of maspin. Cancer Res 64: 1703-1711, 2004.
36. Watanabe M, Nasu Y, Kashiwakura Y, Kusumi N, Tamayose K, Nagai A, Sasano T, Shimada T, Daida H and Kumon H: Adeno-associated virus 2-mediated intratumoral prostate cancer gene therapy: long-term maspin expression efficiently suppresses tumor growth. Hum Gene Ther 16: 699-710, 2005.
37. Lockett J, Yin S, Li X, Meng Y and Sheng S: Tumor suppressive maspin and epithelial homeostasis. J Cell Biochem 97: 651-660, 2006.
38. Marioni G, Blandamura S, Giacomelli L, Calgaro N, Segato P, Leo G, Fischetto D, Staffieri A and de Filippis C: Nuclear expression of maspin is associated with a lower recurrence rate and a longer disease-free interval after surgery for squamous cell carcinoma of the larynx. Histopathology 46: 576-582, 2005.
39. Mohsin SK, Zhang M, Clark GM and Craig Alfred D: Maspin expression in invasive breast cancer: association with other prognostic factors. J Pathol 199: 432-435, 2003.